<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04569409</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-ASC-DFU-302</org_study_id>
    <nct_id>NCT04569409</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.</brief_title>
  <official_title>Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers: A Randomized, Comparator-controlled, Double-blind, Parallel-group, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in&#xD;
      patients with Diabetic Wagner grade 2 Foot Ulcer, compared to placebo therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental: ALLO-ASC-DFU, Placebo Comparator: Vehicle Sheet, Study type: Interventional,&#xD;
      Study design: Randomized, Placebo-controlled, Double blind, Parallel-group, Multi-center&#xD;
      Study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure</measure>
    <time_frame>During 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time taken to complete wound closure</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects who achieved complete wound closure at every visit</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change rates in wound size and depth compared to baseline groups</measure>
    <time_frame>During 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>ALLO-ASC-DFU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle sheet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hydrogel sheet without allogenic mesenchymal stem cell</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-ASC-DFU</intervention_name>
    <description>Application of ALLO-ASC-DFU sheet to Diabetic Wagner grade 2 Foot Ulcer</description>
    <arm_group_label>ALLO-ASC-DFU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vehicle Sheet</intervention_name>
    <description>Application of Vehicle sheet to Diabetic Wagner grade 2 Foot Ulcer</description>
    <arm_group_label>Vehicle sheet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is between 19 and 75 years of age.&#xD;
&#xD;
          2. Subject is diagnosed with Type I or Type II diabetics.&#xD;
&#xD;
          3. Diabetic foot ulcer has been more than 4 weeks but less than 52 weeks at the screening&#xD;
             visit.&#xD;
&#xD;
          4. Ulcer located in the foot and ulcer size is between 1.5~15 cm2.&#xD;
&#xD;
          5. Ulcer graded 2 by Wagner grade.&#xD;
&#xD;
          6. Foot ulcer extended to ligament, tendon, joint capsule, fascia, muscle and periosteum.&#xD;
&#xD;
          7. Ulcer is free of necrotic debris.&#xD;
&#xD;
          8. Ulcer area blood circulation meets one of the following criteria;&#xD;
&#xD;
               -  Blood vessels around the ulcer detected by Doppler Test&#xD;
&#xD;
               -  Range of Ankle Brachial Index (ABI) is &gt; 0.7 to &lt; 1.3&#xD;
&#xD;
               -  Transcutaneous Oxygen Pressure (TcPO2) &gt; 30mmHg or Toe Blood Pressure (TBP) &gt;&#xD;
                  40mmHg.&#xD;
&#xD;
               -  Skin Perfusion Pressure (SPP) &gt; 30mmHg&#xD;
&#xD;
          9. Subject is able to give written informed consent prior to study start and willing to&#xD;
             comply with the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ulcer is of non-diabetic pathophysiology.&#xD;
&#xD;
          2. There is gangrene in any part of the target foot ulcer.&#xD;
&#xD;
          3. The longest dimension of the target foot ulcer exceeds 15 cm at the enrollment visit.&#xD;
&#xD;
          4. Other wounds within 2cm of the target foot ulcer.&#xD;
&#xD;
          5. The ulcer has increased or decreased in size by ≥ 30% during two weeks after the&#xD;
             screening visit.&#xD;
&#xD;
          6. Patient requiring intravenous (IV) antibiotics to treat foot wound infection at the&#xD;
             screening and enrollment visit.&#xD;
&#xD;
          7. Current evidence of active charcot on the study foot, osteomyelitis, cellulitis, or&#xD;
             evidence of other infection including fever or purulent drainage from wound site.&#xD;
&#xD;
          8. Patient with skin lesion confirmed by biopsy (when Investigator deems suspicious) and&#xD;
             then judged by Investigator to be an etiology other than diabetic foot ulcer.&#xD;
&#xD;
          9. An active malignant tumor(malignant melanoma, squamous cell carcinoma, basal cell&#xD;
             carcinoma) on the body or skin.&#xD;
&#xD;
         10. Have a glycated hemoglobin A1c (HbA1c) level of &gt; 14%&#xD;
&#xD;
         11. Have random blood sugar &gt; 450mg/dL&#xD;
&#xD;
         12. Have severe renal failure with creatinine &gt; 3.0mg/dL.&#xD;
&#xD;
         13. Have severe hepatic deficiencies&#xD;
&#xD;
               -  Total bilirubin ≥ 1.5×upper normal limit(UNL)&#xD;
&#xD;
               -  AST, ALT ≥ 2.0×UNL&#xD;
&#xD;
               -  Serum albumin &lt; 2.0mg/dL&#xD;
&#xD;
         14. Is Human Immunodeficiency Virus (HIV) positive&#xD;
&#xD;
         15. Have a known history of allergic or hypersensitive reaction to bovine-derived proteins&#xD;
             or fibrin glue&#xD;
&#xD;
         16. Pregnant or breast-feeding.&#xD;
&#xD;
         17. Is unwilling to use an acceptable method of birth control during the whole study.&#xD;
&#xD;
         18. Have a clinically relevant history of alcohol or drugs abuse at the screening visit.&#xD;
&#xD;
         19. Is not able to understand the objective of the study or to comply with the study&#xD;
             requirements&#xD;
&#xD;
         20. Is considered by the Investigator to have a significant disease which might impact the&#xD;
             study&#xD;
&#xD;
         21. Is considered not suitable for the study by Investigator&#xD;
&#xD;
         22. Have a history of malignancy within the last 5 years (except carcinoma in situ)&#xD;
&#xD;
         23. Is currently or were enrolled in another clinical study within 60 days of screening&#xD;
&#xD;
         24. Have undergone wound treatments with growth factors, dermal substitutes, or other&#xD;
             biological therapies within the last 30 days.&#xD;
&#xD;
         25. Is receiving oral or parenteral corticosteroids, any immunosuppressive, or cytotoxic&#xD;
             agents with unstable dose within the last 30 days&#xD;
&#xD;
         26. Cannot maintain off-loading process and device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SeungKyu Han, MD. Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BaekKyu Kim, MD. Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JunPio Hong, MD. Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JiUng Bak, MD. Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Borame Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>YeongCheol Seo, MD. Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucheon St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SeungKyu Han, MD. Ph D</last_name>
    <phone>+82-02-2626-3333</phone>
    <email>pshan@kumc.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bucheon ST. Mary's Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Bucheon</state>
        <zip>14647</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YeongCheol Seo, MD. Ph D</last_name>
      <email>ycsuh@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Seongnam-si</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BaekKyu Kim, MD. Ph D</last_name>
      <phone>+82-031-787-7224</phone>
      <email>65683@snubh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JunPio Hong, MD. Ph D</last_name>
      <email>joonphong@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borame Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JiUng Bak, MD. Ph D</last_name>
      <phone>+82-02-870-2332</phone>
      <email>alfbskan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SeungKyu Han, MD. Ph D.</last_name>
      <phone>+82-02-2626-3333</phone>
      <email>pshan@kumc.or.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

